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ABSTRACT 49 
 HRAS, NRAS and KRAS isoforms are almost identical proteins that are ubiquitously 50 
expressed and activate a common set of effectors. In vivo studies have revealed that they 51 
are not biologically redundant; however, the isoform-specificity of Ras signaling remains 52 
poorly understood. Using a novel panel of isogenic SW48 cell lines endogenously 53 
expressing wild type or G12V mutated activated Ras isoforms we have performed a 54 
detailed characterization of endogenous isoform-specific mutant Ras signaling. We find 55 
that despite displaying significant Ras activation, the downstream outputs of oncogenic 56 
Ras mutants are minimal in the absence of growth factor inputs. The lack of mutant 57 
KRAS-induced effector activation observed in SW48 cells appears to be representative 58 
of a broad panel of colon cancer cell lines harboring mutant KRAS. For MAP kinase 59 
pathway activation in KRAS mutant cells, the requirement for co-incident growth factor 60 
stimulation occurs at an early point in the Raf activation cycle. Finally, we find that Ras 61 
isoform-specific signaling was highly context dependent and did not conform to the 62 
dogma derived from ectopic expression studies. 63 
INTRODUCTION   64 
 Ras proteins are ubiquitously expressed monomeric GTPases that represent key 65 
signaling hubs operating downstream of growth factor receptors to regulate cell 66 
proliferation, differentiation, protein synthesis, metabolism and cell survival (Pylayeva-67 
Gupta et al., 2011; Hobbs et al., 2016). Activation of Ras generates a network response; 68 
however the most intensively studied effector pathways are the Raf-MEK-ERK and PtdIns 69 
3-kinase (PI3K)-AKT pathways (Cox and Der, 2011). Oncogenic mutations in Ras at 70 
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codons 12, 13 or 61 are present in ~20% of human cancers (Prior et al., 2012). Whilst all 71 
of these mutations are activating, recent work has indicated that each mutation specifies 72 
a distinct Ras output and propensity for promoting oncogenesis (De Roock et al., 2010; 73 
Ihle et al., 2012; Burd et al., 2014; Alamo et al., 2015; Hammond et al., 2015; Stolze et 74 
al., 2015; Winters et al., 2017). 75 
 Three ubiquitously expressed Ras genes (HRAS, KRAS and NRAS) encode at least 4 76 
isoforms that despite being almost identical are not functionally redundant. In vivo 77 
evidence for this comes from studies of mouse development where KRAS knockout mice 78 
are embryonic lethal whereas NRAS and HRAS double knockout mice are healthy (Koera 79 
et al., 1997; Esteban et al., 2001). Mice with HRAS inserted into the KRAS locus are 80 
viable; however, they exhibit cardiomyopathy that suggests that whilst the patterns of 81 
expression and gene dosing define the majority of the isoform-specific effects on 82 
development, there may still be KRAS-specific contributions to healthy development 83 
(Potenza et al., 2005). Other evidence comes from large-scale profiling of the distribution 84 
of oncogenic Ras mutations that reveals an isoform-specific bias, with KRAS being the 85 
most frequently mutated isoform (Prior et al., 2012). Furthermore, comparative studies 86 
using mouse models endogenously expressing activated mutant Ras isoforms reveal that 87 
only KRAS is capable of promoting colonic epithelium proliferation (Haigis et al., 2008). 88 
 The Ras isoform-specific signaling differences underpinning these in vivo differences 89 
remain poorly understood. Ectopic over-expression studies revealed that whilst all Ras 90 
isoforms can activate canonical Raf-MAP-kinase and PtdIns 3-kinase (PI3K)-AKT 91 
pathways, they are differentially coupled. Specifically, KRAS is a better activator of Raf 92 
and Rac whereas HRAS and NRAS are better activators of PI3K (Yan et al., 1998; Voice 93 
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et al., 1999). Notably however, cells derived from KRAS mutant mouse models and 94 
cancer cell lines harboring endogenous mutant Ras frequently do not exhibit the high 95 
levels of PI3K and Raf-MAP kinase pathway activation seen in over-expression studies 96 
(Iida et al., 1999; Yip-Schneider et al., 1999; Giehl et al., 2000; Tuveson et al., 2004; 97 
Omerovic et al., 2008). Similarly, synthetic lethality studies have illustrated the significant 98 
context dependence associated with Ras signaling (Downward, 2015). This means that 99 
any systematic characterization of isoform-specific Ras signaling needs to either be 100 
based on very large panels of cell lines or performed in isogenic model systems where 101 
endogenous signaling is measured. 102 
 Genome edited isogenic cell models allow the study of Ras variants expressed from 103 
endogenous loci whilst avoiding context-dependent differences associated with different 104 
genetic backgrounds. The majority of isogenic cell models have used genetic ablation of 105 
a wild type or oncogenic KRAS allele resulting in some gene dosing differences between 106 
wild type and oncogenic KRAS cells (Shirasawa et al., 1993; Kim et al., 2004; Di 107 
Nicolantonio et al., 2008; Yun et al., 2009). More recently, recombinant adeno-associated 108 
virus (rAAV) targeted genome editing has been used to generate a panel of isogenic 109 
colorectal SW48 cells harboring a range of heterozygous mutations at codons 12 or 13 110 
of the KRAS gene (De Roock et al., 2010). Importantly, each individual mutation 111 
generates a distinct oncogenic and network response (Ihle et al., 2012; Burd et al., 2014; 112 
Hammond et al., 2015); which means that any comparison of isoform-specific oncogenic 113 
Ras signaling should incorporate the same activating mutation in each Ras gene. Taking 114 
this into account we have developed a novel isogenic SW48 cell panel and employed a 115 
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focused network biology strategy to characterize the context-dependence of endogenous 116 
isoform-specific Ras signaling responses.  117 
 118 
RESULTS 119 
An isogenic panel of Ras G12V SW48 cells.  120 
 To investigate endogenous isoform-specific Ras signaling we generated isogenic 121 
NRASG12V cell lines to complement an existing panel of heterozygous G12V mutated Ras 122 
variant SW48 cell lines. The same parental SW48 cells harboring wild type Ras isoforms 123 
and an rAAV-based genome editing strategy were used for the generation of all of the 124 
isogenic cell lines used in this study. The presence of an oncogenic Ras variant results 125 
in no obvious change in the protein abundance of the mutated or wild type Ras isoforms 126 
in each of the isogenic cell lines (Figure 1A). Highly transforming G12V mutations result 127 
in constitutive Ras activation and are present in 20% of human cancers that possess a 128 
mutated Ras (Prior et al., 2012). However, the presence of a G12V mutated Ras isoform 129 
does not result in noticeable activation of canonical Ras effector pathways in the absence 130 
of serum where any signaling will be entirely contingent on the mutant Ras proteins 131 
(Figure 1B). The lack of response in serum-starved cells harbouring hyper-active Ras 132 
isoforms is in significant contrast to the effector activation observed in wild-type cells 133 
stimulated for 5 minutes with 15 ng/ml EGF (Figure 1B). One explanation for this could 134 
be that the absence of growth factors reduced nucleotide exchange on Ras to the point 135 
where G12V induced resistance to GAP-mediated GTP hydrolysis became redundant. 136 
However, this does not seem to be the case since significant Ras activity is detected for 137 
each isoform harboring a G12V mutation (Supplementary Figures 1A & 1B).  138 
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 Standard cell culture conditions in the presence of 10% fetal bovine serum (FBS) 139 
revealed subtle isoform-specific patterns of effector activation, although they do not 140 
exceed the variability observed between KRASG12V clones (Figure 1C). Therefore, mutant 141 
Ras activation of effectors is growth factor-dependent, and in the presence of a cocktail 142 
of growth factors in FBS we found no evidence for isoform specificity of endogenous Ras 143 
coupling to canonical effector pathways. 144 
 The variability in some outputs that we observed between the KRASG12V cells raised 145 
questions about whether our other cells were likely to be representative. We were unable 146 
to generate additional HRASG12V clones; however, we were able to generate a larger 147 
panel of NRASG12V clones and observed similar MAPK pathway outputs to the clone that 148 
we had already selected and some heterogeneity in the AKT pathway response. 149 
(Supplementary Figure 2). The heterogeneity that we observed within the NRASG12V 150 
panel was no greater than that observed between the KRASG12V clones.  Therefore, to 151 
acknowledge the potential for clonality to confound our observations we have included 152 
both KRASG12V clones in all subsequent experiments. Although clonality means that any 153 
subtle differences between isoforms are unable to be clearly described, all clones show 154 
the same growth factor dependence for observing robust activation of canonical Ras 155 
effector pathways. 156 
 157 
Basal downstream signaling is reduced and GF responses are isoform-specific. 158 
  To characterize the wider network responses of endogenous Ras isoform signaling we 159 
performed Luminex analysis incorporating phospho-antibody reporters of the activation 160 
status of 16 relevant downstream and feedback-regulated signaling nodes. Cells under 161 
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basal serum-starved cell culture conditions exhibited no activation of the Ras network in 162 
the presence of any of the constitutively active Ras isoforms (Supplementary Figure 3A). 163 
Indeed, all but 5 of the 64 measurements of Ras effector phosphorylation are decreased 164 
in mutant Ras cells versus wild type Ras Parental cells with both KRASG12V clones 165 
generally displaying the most pronounced levels of Ras network suppression. This may 166 
reflect uncoupling of oncogenic Ras from downstream signaling and/or adaptive 167 
engagement of negative feedback pathways downstream of active Ras to suppress the 168 
network response.  169 
 In response to growth factor stimulation Parental as well as G12V mutant cell lines 170 
exhibit increased activation throughout their Ras network although this is context 171 
dependent (Figure 1D & Supplementary Figure 3B). Within the RAF-MAP kinase pathway 172 
the suppressed outputs in Ras mutant cells compared to Parental control are generally 173 
less evident with co-incident growth factor stimulation. This is particularly clear for all 174 
isoforms following EGF stimulation and for HGF stimulation of AKT in HRAS and KRAS 175 
mutant SW48 cells. EGF is the most potent of the three growth factors at activating the 176 
Raf pathway (pMEK-pERK-pp90RSK) with for example, 10-15-fold increases in MEK 177 
activation versus untreated, compared to 2-fold and 4-fold increases respectively 178 
following HGF and IGF stimulation (Figure 1D & Supplementary Figure 3B). In the EGF 179 
condition we also see a trend for an additive effect of HRAS for MEK-ERK activation. 180 
Whilst this suggests enhanced coupling between HRAS and the RAF-MAP kinase 181 
pathway compared to the other Ras isoforms, this is only present in the context of EGF 182 
stimulation and not a general feature of HRAS signaling. Notably, Ras activity is less 183 
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stimulatable by EGF if a cell harbors a mutant Ras isoform (Supplementary Figure 1A & 184 
1C).  185 
 Within the PI3K pathway the significant suppression of KRAS activation of AKT and 186 
RPS6 versus Parental control is lost when cells are stimulated with growth factors. 187 
Strikingly, we observe potent activation of AKT and RPS6 in HGF-stimulated KRAS 188 
mutant SW48 cells compared to the other cell lines (Figure 1D & Supplementary Figure 189 
3B). Therefore, analogous to HRAS coupling to the RAF pathway, KRAS coupling to the 190 
PI3K-AKT pathway is also highly context dependent and not a generic feature of 191 
endogenous isoform-specific Ras signaling.  192 
 193 
Generation of perturbation data to systematically probe signaling.   194 
 In order to get a deeper understanding, we used a network biology approach where 195 
responses to pathway manipulations can be used to inform mathematical models that 196 
predict signaling flow within a network (Klinger et al., 2013). To generate the data for 197 
mathematical modeling we performed, in addition to the stimulation experiments depicted 198 
in Figure 1D, a broad range of combinatorial treatments targeting the Ras signaling 199 
network (Figure 2A). Specifically, we stimulated the indicated isogenic SW48 cells for 20 200 
minutes with empirically determined sub-saturating doses of three growth factors: EGF, 201 
HGF and IGF. The cells had been pre-incubated for 1 hour with pharmacological inhibitors 202 
of MEK, PI3K, MTOR, Src or solvent control and the phosphorylation status of 16 203 
members of the local Ras signaling network was measured in a Luminex proteomics 204 
platform (Figure 2B, Supplementary Figure 4). The presence of inhibitors was maintained 205 
whilst co-incident growth factor stimulation was performed. The 20 minutes stimulatory 206 
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time point was chosen because it represented signaling in an approximate steady state 207 
during the long-term plateau phase that follows the initial strong transient peak (Klinger 208 
et al., 2013). 209 
 Whilst generally there are subtle differences between cell lines in response to 210 
combinatorial treatments, AKT and MEK activation in HGF-stimulated KRAS cells are the 211 
most obvious outliers (Figure 2B, Supplementary Figure 4). All cell lines show >10-fold 212 
up-regulation of MEK phosphorylation in the presence of MEK inhibitor in EGF-stimulated 213 
cells that would be consistent with the loss of ERK–dependent negative feedback.  214 
 215 
Modeling unveils subtle interlineal differences and a clear overall effect on 216 
signaling.  217 
 Luminex measurements were incorporated into mathematical models of network 218 
connectivity. We quantified the feed-forward and feedback relationships within a core 219 
network around Ras in each cell line using mathematical modeling. The algorithm 220 
determines network structure and parameterizations based on modular response 221 
analysis (MRA) (Klinger et al., 2013) (Figure 3A). The model pipeline estimates response 222 
coefficients for an initial literature-based network and then iteratively edits the network to 223 
generate the best consensus network for the whole dataset derived from the perturbation 224 
experiments (Figure 3B point 1 to 2). Afterwards, significantly differing parameters across 225 
datasets are derived by first modeling all datasets with the same parameter set and then 226 
iteratively testing if individual fitting of each parameter significantly improved the overall 227 
fit (likelihood ratio test, p ≤ 0.05). Of the 21 parameters tested 10 were required to be 228 
fitted specifically to each dataset. Looking at the localization of the edges where variability 229
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was observed between the Ras mutant SW48 cells (Figure 3B, point 3) we can see that 230 
mainly the upstream signaling is different in the cell lines as 5 of the 6 receptor-associated 231 
parameters have to be differential whereas 8 of the 10 links downstream of ERK and AKT 232 
can be modeled with the same parameter (dashed links). When looking at the variation 233 
size of the differential signaling parameters across cell line models (as absolute 234 
coefficient of variation (CV)), 3 parameters (ERK-RAF feedback and MET downstream 235 
links) have to be varied strongly (CV > 1) whereas the remaining 7 only required minor 236 
changes (CV < 0.5). Thus, by individually modeling 10 of the total 24 parameters 237 
(including the 3 quantifications of inhibitor strengths that were not allowed to vary between 238 
cell lines) we can simulate cell-line specific responses that are in good agreement with 239 
the experimental data (Figure 3C). In order to more closely study the differential signaling, 240 
we clustered the cell lines according to the 10 variable parameters (row-wise normalized 241 
to absolute maximum; Figure 3D). Whilst most represent relatively subtle differences, in 242 
general the KRAS clones differentiate from the other cell lines across each of the 243 
parameters. The most striking differences are seen for HGF-induced activation of the RAF 244 
pathway and EGF/HGF/IGF-induced activation of the PI3K pathways that in each case is 245 
strongest in the KRAS mutant SW48 cells.  246 
 Apart from modeling individual Ras-isoform-specific models, we also applied a holistic 247 
model that included all datasets and modeled Ras mutations as perturbations of the 248 
Parental state. This allowed us to dissect the direct impact of the Ras mutation on their 249 
downstream outputs, using the previously defined network topology (see Figure 3B point 250 
2). We found that all Ras mutations had a negative impact on signaling via PI3K and Raf 251 
versus Parental cells in each cellular context (Supplementary Figure 4). Specifically, we 252 
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find that basal signaling (in the absence of growth factors) is trending downwards in Ras 253 
mutant SW48 cell lines and their growth factor inducibility is decreased compared to 254 
Parental cells. 255 
 256 
RASG12V signaling is attenuated upstream of RAF and requires receptor 257 
stimulation.  258 
 The network analysis reinforces our earlier observation that active Ras mutants do not 259 
exhibit potent effector stimulation in the absence of growth factors (Figure 1B), but the 260 
mechanism remains unclear. To address this, we focused on the Raf-MAP kinase 261 
pathway and considered each of the points where the signal could be interrupted or 262 
remodeled (Figure 4A). Phosphorylation of Ser259 on CRAF provides a 14-3-3 binding 263 
site that stabilizes CRAF in an auto-inhibited state unable to bind to Ras (Lavoie and 264 
Therrien, 2015). We observed a trend for reduced phosphorylation in the presence of 265 
growth factors but not RAS mutation alone (Figure 4B). The differences are marginal, and 266 
difficult to infer whether there will be consequences in the capacity for mutated RAS SW48 267 
cells to recruit Raf to the membrane. However, Raf heterodimerization that occurs 268 
downstream of Ras recruitment was only seen in the presence of growth factor stimulation 269 
(Figure 4C). Oncogenically mutated KRAS was unable to promote Raf dimerization in the 270 
absence of growth factors suggesting either that Raf has not been efficiently recruited to 271 
the membrane or that dimerization is sensitive to co-incident growth factor signaling. 272 
Phosphorylation of Ser338 in the catalytic domain of CRAF indicates a fully active Raf 273 
molecule (Lavoie and Therrien, 2015). Clear growth factor dependence is seen for 274 
activating phosphorylation of CRAF and downstream effectors (Figure 4D & 4E). Finally, 275 
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we explored whether negative feedback was actively down-regulating mutant RAS 276 
signaling. Negative feedback phosphorylation of Ser289/296/301 on CRAF is mediated 277 
by activated ERK (Lavoie and Therrien, 2015), and we saw clear sensitivity of these sites 278 
to MEK inhibition following EGF stimulation but not in the starved condition when any 279 
MEK-ERK activation would be driven exclusively by mutant RAS (Figure 4F, 280 
Supplementary Figure 5). Therefore, the low levels of MEK-ERK phosphorylation seen in 281 
mutant RAS SW48 cells in the absence of growth factor stimulation are not a cause or 282 
consequence of negative feedback to CRAF. Together, these data demonstrate that 283 
oncogenically mutated RAS in our cells is unable to activate the Raf-MAP kinase pathway 284 
in the absence of co-incident growth factor stimulation and that the requirement for growth 285 
factors is evident from early in the Raf activation cycle. 286 
 287 
Oncogenic Ras decoupling from effector pathways is also observed in a wider 288 
colorectal cancer cell panel. 289 
 There are no independent isogenic systems with equivalent mutations in each of Ras 290 
isoforms that we could use to increase confidence in the wider applicability of our findings. 291 
Instead we assembled a panel of colorectal cancer cell lines variously containing 292 
mutations in Ras pathway components (Figure 5A). Quantitation of Western blots from 293 
biological replicates reveals that KRAS mutation status does not define the effector 294 
response and co-clustering of mutant and wild-type KRAS cell lines is observed (Figure 295 
5B). Notably, there is no evidence of effector stimulation in a subset of KRAS mutant cell 296 
lines with only 7/11 pMEK and 6/11 pAKT responses in KRAS mutant cells displaying 297 
increased phosphorylation versus wild type SW48 cells and only 1/11 KRAS mutant cell 298 
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lines showing strong pAKT increases (Figure 5A). This is consistent with the observations 299 
in the SW48 cell panel where the presence of mutated Ras did not lead to AKT or MEK 300 
phosphorylation in the serum-starved context (Figure 1B). We confirmed that the KRAS 301 
mutations are functional with all codon 12, 13 and 61 mutants exhibiting clear increases 302 
in KRAS activity compared to the wild type KRAS cell lines (Figure 5B). The A146T 303 
mutation that is observed in <0.05% of colon cancers had a negligible effect on LIM1215 304 
cell KRAS activity. A lack of correlation between the amount of KRAS activity and effector 305 
activation is seen regardless of the presence or absence of co-incident mutations (Figure 306 
5C). Similarly, in a wider Luminex-based analysis of Ras network activation we see that 307 
mutation status does not define the co-clustered responses, with the exception of pMEK 308 
responses in BRAF mutant cells (Figure 5D), and this data reemphasizes that cells with 309 
KRAS mutations show no general trend of increased signaling. In summary, data 310 
generated using the SW48 panel are consistent with a subset of colon cancer cell lines 311 
harboring mutant KRAS that also exhibit negligible effector activation in the absence of 312 
growth factors despite harboring activated KRAS. 313 
  314 
DISCUSSION 315 
 Isoform-specific Ras signaling has been inferred from studies of mouse development 316 
and cancer mutation frequencies (Koera et al., 1997; Esteban et al., 2001; Prior et al., 317 
2012); however, we still only have a vague understanding of the isoform-specific 318 
mechanisms that may underpin this. Classic studies ectopically expressing Ras isoforms 319 
suggested clear differences in coupling of RAF and PI3K pathways to Ras isoforms (Yan 320 
et al., 1998; Voice et al., 1999; Hobbs et al., 2016). Whilst amplification of Ras is observed 321 
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in some tumours, it is also true that over-expression can have distorting effects on 322 
signaling networks and senescence rather than an oncogenic program is observed in 323 
some Ras models (Sarkisian et al., 2007). Isogenic cells provide a useful option for 324 
studying variants of endogenous signaling networks without being confounded by 325 
differences in the genetic backgrounds of the various cell lines. To date, isogenic cell-326 
based studies have largely focused on comparative analysis of KRAS mutant versus wild 327 
type Ras cells (Vartanian et al., 2013; Alamo et al., 2015; Stolze et al., 2015). Given the 328 
clear evidence for Ras mutation-specific signaling (Burd et al., 2014; Hammond et al., 329 
2015; Winters et al., 2017), we used the same G12V mutation in all three Ras isoforms. 330 
This novel cell line panel means that we have been able to perform the first analysis of 331 
endogenous isoform-specific Ras signaling in the same genetic background. 332 
 A notable initial observation was the general inability of G12V-mutated Ras isoforms 333 
to generate enhanced RAF and PI3K pathway signaling outputs compared to the wild 334 
type control (Figure 1B). G12V mutant Ras displays slow nucleotide exchange and slow 335 
GTP hydrolysis (Trahey et al., 1987; Smith et al., 2013), meaning that starvation and 336 
stimulation times could significantly influence the amount of active Ras in the cell. 337 
However, under the conditions in which we performed the experiments it was clear that 338 
the lack of effector activation was not due to a lack of Ras activation (Supplementary 339 
Figure 1A). It is relevant to note that SW48 cells harbor an EGFRG719S mutation that has 340 
been observed to promote ligand-independent EGFR kinase activity and Ras effector 341 
activation (Greulich et al., 2005); and might be expected to exhibit pre-existing 342 
engagement of negative feedback pathways. However, we saw no evidence for this under 343 
our experimental conditions; all of the isogenic cell lines showed significant EGF 344 
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stimulatability, effector activation was minimal under serum-starved conditions and 345 
negative feedback was only consistently observed when EGF was added to cells 346 
(Supplementary Figure 5). 347 
 One potential criticism of our cell model is that the introduction of Ras oncogenic 348 
mutations into a wild type Ras SW48 cell parental background does not result in Ras 349 
addiction that is observed in some cancer cell lines in some contexts. Therefore, the 350 
signaling that we are observing may not be equivalent to “true” oncogenic mutant Ras 351 
signaling. In fact, DepMap analysis reveals that <30% of 2-D cultured KRAS mutant cell 352 
lines show strongly selective KRAS dependence (Tsherniak et al., 2017). Furthermore, 353 
our observation of low levels of effector activation in Ras mutant SW48 cells has been 354 
seen before in a range of Ras mutant cancer cells and mouse models (Iida et al., 1999; 355 
Yip-Schneider et al., 1999; Giehl et al., 2000; Tuveson et al., 2004; Omerovic et al., 2008; 356 
Vartanian et al., 2013). We also observed a disconnect between the presence of 357 
activating KRAS or PIK3CA mutations and activation of their effector pathways in a panel 358 
of colon cancer cell lines commonly used to study KRAS and cancer biology (Figure 5). 359 
Our observations of Ras versus effector activation seen in the wild type and KRAS mutant 360 
SW48 cells sat well within the range of observations seen within the representative panel 361 
of colon cancer cell lines. Together, these argue against any exceptionalism for the 362 
isogenic SW48 model and the subtle effects on downstream signaling that are observed 363 
in the Ras mutant cells. 364 
 Importantly, studies across a wide range of Ras mutant cell models have usually not 365 
had access to an equivalent matched wild type Ras cell line for comparison so it has not 366 
generally been obvious that mutations that generate hyper-activated Ras can fail to result 367 
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in enhanced outputs compared to wild type Ras. It may be that the chronic trickle of low-368 
level effector activation represents the reality of oncogenic signaling until the acquisition 369 
of genetic insults that further dysregulate signaling later in the progression of the cancer. 370 
Indeed, this low level signaling may be important for avoiding pushing the cells into 371 
cytotoxic stress, cell death or senescence (Varmus et al., 2016). 372 
 Stimulation with growth factors potently activated Ras effectors (Figures 1 & 2); 373 
therefore, the lack of signaling seen in the Ras mutant cells was not due to a complete 374 
down-regulation or uncoupling of the Ras network. The second feature of the growth 375 
factor stimulation experiments was that Ras isoforms variably display enhanced coupling 376 
to the RAF and PI3K pathways (Figure 1D). However, these were not consistent across 377 
all growth factor stimulations (Figure 2) and the patterns did not conform to the 378 
observations seen in ectopic expression studies where KRAS preferentially coupled to 379 
Raf-MAP kinase and HRAS coupled to the PI3K pathway (Yan et al., 1998; Voice et al., 380 
1999). Therefore, the dogma that Ras isoforms consistently favor coupling to a particular 381 
Ras pathway is incorrect in this endogenous context and the reality is far more nuanced 382 
and subject to growth factor modulation. 383 
 Mathematical modeling of the combinatorial treatment data revealed that the core 384 
signaling networks are very similar between the Ras isoforms (Figure 3). Nevertheless, 385 
there were some significant differences between the Ras isoforms that tended to 386 
distinguish the KRAS cell lines from the rest. The most pronounced of these differences 387 
were the increased GF-induced pathway activation (Figure 3D). HGF was particularly 388 
selective for KRAS-dependent PI3K pathway activation and this observation can be 389 
explained by the increased expression of the HGF receptor MET in KRAS mutant cell 390 
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lines including both G12V clones (Hammond et al., 2015). Although MET is upstream of 391 
KRAS, it has a well-established role in Ras-dependent tumorigenesis that typically 392 
involves gene and protein amplification consistent with our observations (Webb et al., 393 
1998; Furge et al., 2001; Xie et al., 2012; Hammond et al., 2015).   394 
 Importantly, the modeling did not point to a profound rewiring of the Ras network that 395 
could explain the minimal effector activation in the absence of growth factors. Similarly, 396 
our experiments to profile where the signaling downstream of Ras might be interrupted 397 
revealed no evidence for network rewiring. Instead, they suggested that mutant Ras in 398 
serum-starved cells was unable to efficiently activate Raf (Figure 4), arguing that growth 399 
factor signaling is required to give competence to Ras activation of this key effector 400 
pathway. Insufficiency may arise due to the coordinated regulation of kinases, 401 
phosphatases, scaffolds and cofactors required for Raf-MAPK activation (Figure 4A) 402 
(Lavoie and Therrien, 2015). In this context, growth factor receptor engagement of a wider 403 
signaling network than Ras could be required to create a permissive state for efficient 404 
Ras signaling. We note that ectopic expression studies have shown downstream 405 
activation in serum-starved cells when Ras mutants are over-expressed (Yan et al., 1998; 406 
Voice et al., 1999). Whilst this could argue against Ras insufficiency, an alternative 407 
interpretation is that the higher concentration of Ras in cells is able to overcome the 408 
requirement for growth factor signaling to prime the Ras network. Higher Ras 409 
concentrations will influence the nanoscale organization of Ras on the plasma membrane 410 
and increase the opportunity for dimerization and interactions with effectors (Zhou et al., 411 
2017). Alternative explanations for the requirement for growth factors could include a 412 
requirement for SOS recruitment and wild type Ras engagement (Margarit et al., 2003; 413 
 18 
Jeng et al., 2012), that alternative effectors may be preferentially bound in the absence 414 
of growth factors (Adhikari and Counter, 2018), or that nucleotide cycling within the Ras 415 
population may be required for efficient and disease-relevant signaling (Nichols et al., 416 
2018; Ruess et al., 2018). 417 
 An important caveat with these studies is the use of a single isogenic cell model system 418 
and the potential for cell clonality to confound the observations. To give an indication of 419 
potential clonal heterogeneity we profiled a panel of NRAS clones to identify a 420 
representative clone (Supplementary Figure 2) and used more than one KRAS clone 421 
throughout our studies. Whilst it is clear that heterogeneity between clones exists, all of 422 
the clones conformed to the core observations of minimal effector responses to the 423 
presence of mutant Ras and similar substantial context-dependent responses to the 424 
presence of different growth factors. We also observe similar mutant KRAS-refractory 425 
responses in a representative panel of colon cancer cell lines. Whilst data from a single 426 
isogenic system is not definitive, our observations challenge current models and highlight 427 
fundamental aspects of Ras biology requiring further understanding. 428 
 In summary, we have created an isogenic cell panel that for the first time allows 429 
endogenous signaling of all Ras isoforms to be investigated in a common genetic 430 
background. The expression of isoform-specific G12V mutant Ras in the background of 431 
five wild type Ras alleles, all expressed in their native genomic contexts, represents the 432 
earliest stage of Ras-driven cancer. The observed limited activation of key effector 433 
pathways suggests that endogenous oncogenic Ras signaling relies on co-stimulatory 434 
events or further genetic perturbations to overcome cellular homeostasis mechanisms. 435 
These mechanisms are imposed at the earliest points in the effector activation cycle. 436 
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Differences between Ras isoform outputs were most clearly revealed with concomitant 437 
growth factor stimulation where it operated as a subtle but variable nudge on the 438 
significant growth factor-induced program. This is likely to be critical in the context of the 439 
tumour microenvironment where mutated Ras will operate in the presence of a cocktail 440 
of growth factors. Our systematic analysis reveals that the long-held view that Ras 441 
isoforms are consistently coupled to particular effector pathways is likely to be over 442 
simplistic and that the context dependence of HRAS, NRAS and KRAS signaling 443 
precludes any general predictions of likely pathway activation in response to a specific 444 
isoform. 445 
 446 
 447 
MATERIALS AND METHODS 448 
Reagents. The following inhibitors were used in various assays: AZD6244 (5µM; MEK; 449 
Selleck Chemicals), LY294002 (20µM; PI3K; Alexis Chemicals), Rapamycin (0.15µM; 450 
TOR; Selleck Chemicals), Dasatinib (25 nM; Src; Selleck Chemicals). The solvent control 451 
was DMSO (equal volume to each inhibitor). The following ligands were used (all 452 
Peprotech): IGF-1 (50 ng/ml), EGF (15 ng/ml) and HGF (50 ng/ml) with 0.1% BSA in PBS 453 
as solvent.  454 
 455 
Cell lines. Ras mutation sequence verified isogenic SW48 cells were obtained from 456 
Horizon Discovery. The clones used were HRASG12V (clone 1), KRASG12V (clone c16 (K1) 457 
and clone c48 (K2)). Heterozygous knock-in of NRASG12V (clone G9-1 (N1), clone 7-2 458 
(N2), clone 4-2 (N3), and clone 8-1 (N4)) was generated from homozygous RASWT 459 
Parental SW48 cells, using AAV-mediated gene editing and sequence verified for the 460 
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presence of a heterozygous NRAS G12V mutation. SW48 cells were grown in McCoy’s 461 
5A media, supplemented with 10% [v/v] FBS, 100 units/ml penicillin and 100 µg/ml 462 
streptomycin (Thermo Fisher Scientific), at 37ºC in 5% [v/v] CO2. The colon cancer cell 463 
panel comprising Caco-2, LIM1215, Colo205, Vaco432, RKO, SW837, Colo678, LS180, 464 
SW480, SW620, LoVo, T84, HCT8, HCT116, SW948 were cultured in DMEM (BE12-465 
707F, Lonza/Biozym), supplemented with 1%Ultraglutamine (BE17-605E/U1, 466 
Lonza/Biozym), 100 units/ml penicillin and 100 µg/ml streptomycin (DE17-602E, 467 
Lonza/Biozym) and 10% [v/v] FBS (P30-1506, PAN Biotech) at 37°C and 5% CO2. 468 
Vaco432 cells were obtained from René Bernards lab (NKI), all other cell lines from AG 469 
Sers (Charité). All cell lines were Short tandem repeat (STR)-authenticated via Eurofins 470 
Genomics. Vaco432 could not be matched, as they were not found in the database. 471 
Mycoplasma testing was conducted by Eurofins Genomics. 472 
 Starvation of cells was done for 16h with FBS-free medium, before lysis. Lysis was 473 
done with the lysis Buffer from the Ras activation assay and protease inhibitors there 474 
included. For WB lysates, protease- and phosphatase inhibitors from Bio-Plex Cell Lysis 475 
Kit (Biorad ,171-304012) were used. Protein concentration was determined using BCA 476 
Protein Assay Kit (Pierce™,23227). After SDS-PAGE, proteins were blotted to 477 
nitrocellulose membranes and stained with Pierce™ Reversible Protein Stain Kit, wich 478 
was later used for normalisation. The following Abs were used: Rabbit anti-pMEK 479 
(CST9154), Rabbit anti-pAkt T308 (CST9275), Rabbit anti-pAkt S473 (CST4060), Rabbit 480 
anti-pERK (CST4370), Mouse anti-pERK (CST9106). The blots were imaged with 481 
Odyssey CLx and infrared labelled antibodies (all Li-Cor). Analysis was done using 482 
ImageJ after exporting pictures from ImageStudio (Li-Cor). 483 
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 484 
Luminex assays. Cell lysates were prepared using the Bio-Plex Pro™ Cell Signaling 485 
Reagent Kit (Bio-Rad), according to manufacturer’s instructions. Briefly, cells seeded into 486 
24 well plates were serum starved for 24 hours then incubated ±inhibitors in serum-free 487 
media for 1 hour, followed by a 20 minute stimulation ±growth factor in the continued 488 
presence of inhibitor. Lysates were measured with a Bio-Plex Protein Array (Bio-Rad, 489 
Hercules, CA) as described earlier (Klinger et al., 2013) using magnetic bead-based 490 
ELISAs specific for phospho-AKTS473 (171-V50001M), phospho-c-JunS63 (171-V50003M), 491 
phospho-EGFRY1068 (171-V50004M), phospho-ERK1/2T202,Y204/T185,Y187 (171-V50006M), 492 
phospho-GSK3A/BS21/S9 (171-V50007M), phospho-IkBaS32,S36 (171-V50010M), phospho-493 
JNKT183,Y185 (171-V50011M), phospho-MEK1S217,S221 (171-V50012M), phospho-494 
mTORS2448 (171-V50033M), phospho-p38T180,Y182 (171-V50014M), phospho-p53S15 (171-495 
V50034M), phospho-PI3KY458 (171-V50036M), phospho-RPS6S235,S236 (171-V50038M), 496 
phospho-p90RSKS380 (171-V50035M), phospho-SMAD2S465,S467 (171-V50019M) and 497 
phospho-SrcT416 (171-V50039M). The capture antibody-coated beads as well as 498 
detection antibodies and the fluorescent conjugate SAPE were diluted 1:3. We used the 499 
R package lxb for data acquisition and normalized the data as described in Supplemental 500 
File 1. Statistical testing on excerpts of the luminex assay (i.e. Figure 1D, Supplementary 501 
Figure 3) was conducted by applying a one-way-ANOVA (analysis of variance) on 502 
logarithmized data of each subplot followed by multiple correction testing (Benjamini-503 
Hochberg). For significant findings (FDR≤0.05) a post-hoc analysis was conducted 504 
(Tukey’s Honestly Significant Difference test) to report adjusted p-values for the 505 
comparisons of interest. 506 
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 507 
Model construction and evaluation. The modeling procedure relies on a variant of 508 
modular response analysis (MRA) (Klinger et al., 2013) that quantifies identifiable 509 
parameter (combinations) of a given network structure on base of systematic perturbation 510 
data. The network structure was derived from available literature and prior modelling 511 
approaches of colorectal cancer cell lines (Klinger et al., 2013). Modeling was conducted 512 
in the two steps network structure determination and differential signaling detection: (1) 513 
Five cell line-specific models were generated based on the literature network choosing 514 
the best of 3x104 sample runs, observing that the ranked fits converged on the lower end 515 
and multiple best fits were found. These data sets were then locally adjusted to the data 516 
by determining superfluous links, i.e. removal did not significantly decrease the fit 517 
(likelihood-ratio test p>0.05), and missing links, i.e. addition, significantly improved the fit 518 
(Benjamini-Hochberg corrected p≤0.05) in all five cell lines. Among the extension 519 
candidates only those were included, for which a biological confirmation could be found 520 
in the literature (e.g. PI3K -> Raf). (2) The generated consensus network was then used 521 
to train a modelset (4x104 simulations) which models the individual data sets by a single 522 
parameter set. In order to determine significantly differing parameters, modelset 523 
parameters were iteratively relaxed to fit cell line-specific data (i.e. a split up of one 524 
parameter into five) in a greedy hill parameter splitting procedure with ensuing reverse 525 
lumping procedure (likelihood-ratio test p≤0.05, best of 10³ simulations each). 526 
 The holistic model (Supplementary Figure 4) used the found consensus network above 527 
but treated Ras mutations as perturbations of the parental dataset, essentially modelling 528 
all datasets by one model with nodes of the Ras mutations added and each linked to RAF 529 
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and PI3K (105 simulations). The model was run on either the whole dataset or on datasets 530 
without stimulations. All modeling steps were conducted using the R package STASNet 531 
(Version 1.0.0) available under https://github.com/molsysbio/STASNet 38 as described in 532 
Supplemental File 2.  533 
 534 
Ras activation assay and co-immunoprecipitation. Ras activity assays were 535 
performed as described using the Ras Activation Assay Kit (Cytoskeleton, BK008). 536 
Briefly, cells were serum starved for 24 hours, before incubation ±15 ng/ml EGF for 20 537 
minutes, lysis and incubation of 300µg of pre-cleared lysate with 30 μl (100 μg) GST-538 
Raf1-RBD-conjugated sepharose beads for 1 hour at 4 ˚C with rotation. Controls using 539 
serum-starved SW48 Parental cell lysates incubated with 1-3 mM GDP (100% inactive 540 
Ras), and 200 µM GTPgS (100% active Ras) were included for comparative normalisation 541 
of cell lines. For co-immunoprecipitation, cell lysates were prepared using NP40 lysis 542 
buffer (50 mM Tris-HCl, pH7.5, 150 mM NaCl, 1 % NP40 substitute protease inhibitor 543 
cocktail (P8465; Sigma), phosphatase inhibitor cocktail (PhosStop; Roche), 2 mM NaF).  544 
1.5 mg lysate was pre-cleared with protein A-conjugated agarose (Sigma) then incubated 545 
with 2 μg BRAF antibody (Santa Cruz sc-5284) or normal mouse IgG Control (EMD 546 
Millipore, 12-371) and 7.5 μl (4.5 mg) Protein A agarose, for 2.5 hours. Beads from 547 
activity/co-precipitation experiments were washed and then boiled in sample buffer to 548 
elute proteins for loading on 4-12% NuPAGE Bis-Tris gels and visualisation by Western 549 
blotting. The following primary antibodies were used for Western blotting including for 550 
experiments measuring isoform-specific Ras activity; rabbit monoclonal pan-RAS (52939) 551 
phospho-CRAFS259 (173539; both AbCam), KRAS (Life Span Biosciences LS-C175665), 552 
 24 
HRAS (sc-520), NRAS (sc-31), BRAF (sc5284), EGFR sc-03; all Santa Cruz), CRAF 553 
(9422), phospho-CRAFS289/S296/S301 (9431), phospho-CRAFS338 (9427), MEK (9122), 554 
phospho-MEKS217/S221 (9154), ERK (4695), phospho-ERK1/2T202/Y204 (4370), AKT (9272), 555 
phospho-AKTS473 (4060), phospho-EGFRY1068 (2234), actin (6276; all Cell Signaling 556 
Technology).  557 
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FIGURE LEGENDS 723 
Figure 1.  Context-dependent activation of canonical Ras effectors by endogenous Ras 724 
isoforms. (A) Ras isoform protein expression is similar to Parental (P) control in all 725 
isogenic cell lines. (B) The presence of an oncogenic RasG12V allele is insufficient to 726 
activate effector pathways in the absence of co-incident growth factor stimulation. (C) 727 
There are no clear isoform-specific effects on effector activation in response to cell culture 728 
in the presence of 10% FBS. Western blotting data representative of n≥3 biological 729 
replicates. (D) Luminex-based measurement of key nodes within the Ras signaling 730 
network in untreated and growth factor-stimulated cells reveals that differential coupling 731 
of Ras isoforms with the RAF (pMEK, pERK, pp90RSK) or PI3K PI3K (pAKT, pMTOR, 732 
pRPS6) pathways is not a generic feature of Ras signaling; mean ±SD of n=2 biological 733 
replicates. p-values correspond to Tukey’s test (versus Parental) for those cases where 734 
multiple testing corrected one-way-ANOVA was significant (FDR≤0.05); * p<0.05, **, 735 
p<0.01, *** p<0.001. 736 
 737 
Figure 2. Generation of systematic perturbation data. (A) Schema depicting stimulated, 738 
inhibited and measured nodes within the Ras signaling network that were used for 739 
generation of systematic perturbation data. (B) Log2-fold changes (FC) of phosphorylation 740 
in response to combinations of growth factor stimulation and node inhibition across the 5 741 
isogenic SW48 cells lines measured with Luminex-based phospho-assays are displayed. 742 
Values are averaged signals from n=2 biological replicates normalized to the untreated 743 
Parental cell line control (BSA treated control lane).  744 
 745 
 31 
Figure 3. Model fit reveals Ras isoform-specific differences in network topology. (A) 746 
Workflow of modeling steps to determine differential signaling based on Modular 747 
Response Analysis (MRA). (B) Realization of modeling steps from A: the starting network, 748 
consensus network with pruned (red) and extended (blue) links (chi2-test, p≤0.05) and 749 
the resultant differential signaling network of which the numbers and line width reflect 750 
differential signaling across the five cell lines as absolute coefficient of variation (CV) of 751 
the parameter quantifications and dashed links denote unvaried links. (C) Side-by-side 752 
comparison of experimental data (black) and model simulations (yellow) derived from the 753 
final model (step 3 in B). (D) Clustered heatmap of the variable network parameters with 754 
each row scaled by the absolute maximal value.  755 
 756 
Figure 4. Oncogenically mutated Ras requires co-incident growth factor stimulation to 757 
activate Raf. (A) The Raf activation cycle. (B) RAF auto-inhibitory phosphorylation is 758 
largely unchanged by Ras mutation. (C) Growth factor dependence is observed with 759 
BRAF:CRAF heterodimerization, (D) Activating phosphorylation of the CRAF kinase 760 
catalytic domain, (E) downstream activation of CRAF effectors, and (F) ERK-mediated 761 
negative feedback to CRAF revealed by decreased CRAF phosphorylation in the 762 
presence of MEK inhibitors. All blots are representative of n≥3 biological replicates. 763 
Graphs depict mean values ±SEM; paired, equal variance t-test versus Parental cells or 764 
indicated pair-wise comparisons, * p<0.05, ** p<0.01, *** p<0.001, n=3 biological 765 
replicates. Cells starved for 24 hours (EGF -), ±15ng/ml EGF stimulation (EGF +) for 5 766 
minutes for all experiments except 20 minutes for feedback experiment. 767 
 768 
 32 
Figure 5. Ras effector activation does not correlate with KRAS mutation status in a panel 769 
of colon cancer cells. (A) Mutation status of a representative panel of colorectal cancer 770 
cell lines. Representative Western blots from n=2-4 biological replicates indicate that the 771 
presence of an oncogenic mutation is not necessarily leading to activation of effector 772 
pathways in the absence of co-incident growth factor stimulation. (B) Quantification of 773 
KRAS activity measured using a Raf RBD assay (see (A) for representative blot) indicates 774 
that codon 12, 13 and 61 mutant cells contain activated KRAS (mean ± SEM; n=3). (C) 775 
KRAS activity does not correlate with ERK and AKT phosphorylation. (D) Luminex-based 776 
measurement of key nodes within the Ras signaling network reveals that responses do 777 
not strictly co-cluster based on mutation status. Values are averaged signals from n=2-6 778 
biological replicates normalized to the SW48 cells. In all experiments, cells were starved 779 
for 16 hours prior to assaying. 780 
 781 
Supplementary Figure 1.  Oncogenic Ras is active in the absence of growth factor 782 
stimulation. (A) Ras activity in isogenic SW48 cells measured using a Raf RBD assay. 783 
GDP represents 100% inactive Ras and GTPgS indicates 100% active Ras. (B) 784 
Quantification of Ras activity (n=3) indicates that all G12V mutated isoforms are 785 
significantly activated versus wild type control cells. (C) Mutated Ras isoforms display 786 
impaired responsiveness to EGF stimulation. Western blot data are representative of n=3 787 
experiments. Graphs depict mean values ±SEM; paired t-test, * p<0.05, ** p<0.01. 788 
 789 
Supplementary Figure 2.  Profiling Ras signaling in available SW48 cell G12V Ras 790 
clones. Evidence for some clonality is seen with KRASG12V cells. In contrast, the Ras 791 
 33 
signaling outputs from NRASG12V clones are largely homogenous. Cells were grown 792 
under standard cell culture conditions in the presence of 10% FBS. Western blotting data 793 
representative of n=4-7 biological replicates. Graphs of quantified Western blots depict 794 
mean values ±SEM; paired t-test, * p<0.05. 795 
 796 
Supplementary Figure 3. Luminex measurement of Ras network outputs in the panel of 797 
isogenic SW48 cells. (A) Luminex analysis of Ras signaling pathway nodes reveals a lack 798 
of network activation versus the Parental control in serum-starved isogenic SW48 cells. 799 
Data points from technical and biological replicates are shown (circles), bars represent 800 
mean ± SD from n=2 experiments each comprising n=3-8 technical replicates. (B) An 801 
alternative presentation of data from Figure 1D with data grouped by cell line. Data points 802 
indicating n=2 biological replicates. p-values correspond to Tukey’s test (for A versus 803 
Parental, for B versus untreated) for those cases where multiple testing corrected one-804 
way-ANOVA was significant (FDR≤0.05); * p<0.05, **, p<0.01, *** p<0.001. 805 
 806 
Supplementary Figure 4. An alternative presentation of a subset of data from Figure 2B 807 
grouped by cell line. 808 
 809 
Supplementary Figure 5. Parameter heatmap where Ras mutations are modeled as 810 
perturbations. All mutations exert a negative influence on signaling. In the presence (all 811 
data) and absence of growth factors (no GF). Basal signaling versus wild type Ras cells 812 
trends downwards for both PI3K and RAF pathways for all isoforms and shows no clear 813 
 34 
differential isoform-specific effect on downstream outputs (for modeling details refer to 814 
Material and Methods and Supplemental File 2). 815 
 816 
Supplementary Figure 6. ERK-dependent negative feedback to CRAF is independent 817 
of the presence of oncogenic Ras mutants. Blots are from a single experiment and 818 
representative of n=3 biological replicates. Graphs depict mean values ±SEM; n=3; paired 819 
t-test versus Parental cells or indicated pair-wise comparisons, * p<0.05, ** p<0.01, *** 820 
p<0.001. Cells starved for 24 hours, ± 15ng/ml EGF stimulation for 20 minutes, ±5µM 821 
AZD6244 MEK inhibitor, 60 minutes pre-treatment and co-incident incubation during the 822 
EGF stimulation. 823 
 824 
 825 
Supplementary File 1. SW48 Ras isoforms: Normalization. Code for normalizing plate 826 
to plate variability and pre- and post-normalization data. 827 
 828 
Supplementary File 2. Modelling workflow. Code and workthrough of the modeling steps 829 
for network structure determination. 830 
 831 
Supplementary File 3. Ras activity screen. Colorectal cell line panel signaling readout 832 
analysis html containing source data.  833 
 834 
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